metabolic syndrome
Conditions
Interventions
Group A:health lifestyle intervention strengthen firstly, and then select drug treatment according to blood pressure or glucose level
Group B:Physicians who do not known the research program are in accordance with traditional treatment methods to deal with patients
Sponsors
Fuwai Hospital
Eligibility
Sex/Gender
All
Age
20 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Aged 20 to 75 years; 2. Central obesity (waist circumference>=90cm in men, or >=80cm in women)plus two or more of the following: (1) 1.7 mmol/L <= TG<4.07 mmol/L, and TC< 6.24 mmol/L; (2) Fasting plasma glucose (FPG) 5.6 mmol/L<=FPG<7.0mmol/L; (3) 130 mmHg<=SBP<160mmHg, and/or 85 mmHg<=DBP<100 mmHg; (4) HDL-C<1.03 mmol/L (men)or <1.29mmol/L(women); 3. Informed oral consent was obtained from every participant before data collection.
Exclusion criteria
Exclusion criteria: 1. Hypertension (DBP>=110 mmHg and/or SBP>=180 mmHg); use of antihypertensive medications and SBP>=160mmHg and/or DBP>=100 mmHg; 2. Diabetes mellitus; 3. Heart or renal failure, clear angina or recieved CABG or PCI, or Myocardial infarction,stroke, TIA and etc.; 4. Acute infected, malignant and serious arrhythmia, psychiatric disease,drug or alcohol addiction; 5. Allergy or contraindication to research drug; 6. Significantly abnormal liver function or any of the following history of liver disease: 2 times higher than the normal limit of AST or ALT, history of hepatic encephalopathy, history of esophageal varices or portal shunt; 7. Renal function damage or following history of kidney disease: 1.5 times higher than the normal limit of Serum creatinine; history of dialysis; history of nephrotic syndrome; 8. Pregnancy or breast-feeding women; 9. Using other research drugs; 10. Difficulty to follow up, unwilling to cooperate, or existing other impact factors of compliance; 11. Arteriosclerosis obliterans (ASO); 12. Taking lipid-lowering drugs including fibrates or Nicotinic acid drugs (allowing Statins drugs); 13. Using incompatibility drugs with research drug(for example: Erythromycin).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| change of waist circumference, weight, BMI, fasting glucose, TG, HDL-c, SBP, DBP; | — |
Countries
China
Contacts
Public ContactDongfeng Gu
Outcome results
None listed